Lisette Hilton
Lisette Hilton is a writer in Boca Raton, Fla., who heads up her company, Words Come Alive.
Urologists positive about abiraterone integration
More than 96% of urologists surveyed said that incorporating abiraterone acetate (ZYTIGA) treatment into practice for patients with metastatic castrate-resistant prostate cancer is easy or manageable after overcoming initial barriers, according to new research presented at the Genitourinary Cancers Symposium in Orlando, FL.
Software could help prevent post-cystectomy readmission
Researchers have developed software that can generate, in real time, whether a radical cystectomy patient is likely to be rehospitalized and when the urologist should follow up with the patient.
NMIBC guideline compliance remains low
Urologists’ compliance with nonmuscle-invasive bladder cancer guidelines has improved with respect to delivery of perioperative mitomycin, but other care measures continue to be suboptimal, according to a new study.
Surveillance rarely used in stage 1, 2 prostate Ca
Surveillance rarely used in stage 1, 2 prostate Ca
While close to 90% of men diagnosed with prostate cancer between 1998 and 2012 had stage 1 and stage 2 disease, more than 90% underwent surgery or radiation to treat the cancer, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Prostate Ca test influences decision-making post RP
“From our results, the Decipher test helps reassure low-risk patients that observation may be warranted or confirm that high-risk patients need additional treatment,” says study author John L. Gore, MD, MSHS.
Vaginal rejuvenation and the cosmetic practice
It’s proving to be a viable addition to the scope of service in the cosmetic practice, but be forewarned: It’s serious business.
First national urology-wide registry gathers steam
The AUA-sponsored AQUA Registry is gaining momentum as more U.S. urologists choose to sign on with the first national urology-wide registry for quality reporting and more.
Online information linked to PCa treatment regret
Online information linked to PCa treatment regret
Men who use the Internet as their primary source for prostate cancer treatment decision-making are more likely to regret those decisions a year after treatment than those whose primary sources of information are radiation oncologists or urologists.
ASCO issues guidance on second-line hormonal Tx in CRPC
The American Society of Clinical Oncology’s provisional clinical opinion on the use of second-line hormonal therapy for chemotherapy-naïve men with castration-resistant prostate cancer issued by uncovered some surprising findings and issues.
Sleep duration linked to PCa mortality risk in younger men
Results of a recent study support a growing body of evidence that factors associated with circadian rhythm disruption might play a role in prostate carcinogenesis.

Poll

View Results